Abstract
We reviewed our experience with adenosine for the conversion of paroxysmal supraventricular tachycardia (PSVT) to determine whether the recommended dosing strategy of 6 mg, followed by 12 mg, is cost-effective in actual practice. We observed a 65% conversion rate to sinus rhythm with the initial dosage of 6 mg adenosine (95% CI, 54% to 75%), and, based on subsequent cost analysis, conclude that the current strategy should not be replaced by a 12-mg-first strategy. If the packaging of adenosine was changed so that 12 mg cost less than twice 6 mg, this analysis should be revisited.
MeSH terms
-
Adenosine / administration & dosage*
-
Adenosine / economics*
-
Anti-Arrhythmia Agents / administration & dosage*
-
Anti-Arrhythmia Agents / economics*
-
Coronary Disease / complications
-
Coronary Disease / drug therapy
-
Cost-Benefit Analysis
-
Drug Administration Schedule
-
Drug Packaging / economics
-
Emergency Treatment / economics
-
Emergency Treatment / methods
-
Female
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Injections, Intravenous / economics
-
Injections, Intravenous / methods
-
Male
-
Middle Aged
-
Retrospective Studies
-
Tachycardia, Paroxysmal / drug therapy*
-
Tachycardia, Paroxysmal / etiology
-
Tachycardia, Supraventricular / drug therapy*
-
Tachycardia, Supraventricular / etiology
-
Treatment Outcome
Substances
-
Anti-Arrhythmia Agents
-
Adenosine